Sun, Sep. 27, 8:59 AM
- The $8B iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) fell 4.9% on Friday and 13% for the week - its worst weekly performance since the height of the financial panic seven years ago. Many biotech ETFs eat the same cooking - Gilead (NASDAQ:GILD), Amgen (NASDAQ:AMGN), Biogen (NASDAQ:BIIB), and Regeneron (NASDAQ:REGN) among the popular names - and FBT, XBI, and BBP fell in amounts similar to IBB.
- The news flow was relatively quiet late in the week, but Hilary Clinton's promise Monday to clamp down on drug prices set things in negative motion for the momo sector.
- Barron's Chris Dieterich reminds that a flood of biotech IPOs in recent years has filled the small cap universe with these highly speculative names, and biotech now makes up 7% of the iShares Russell 2000 Index (NYSEARCA:IWM). Indeed. The IWM fell 3.7% for the week, nearly tripling the decline of the S&P 500.
- ETFs: IWM, TZA, TNA, UWM, VB, VBK, URTY, SCHA, TWM, IWO, RWM, SRTY, VTWO, RCG, JKJ, VTWG, TWOK, FYX, JKK, EWRS, ZSML, FYC, SMLL, RYRSX
Fri, Sep. 25, 3:07 PM
- A sharply lower healthcare sector (XLV -3%) has dragged the S&P 500 (SPY -0.2%) into the red and the Nasdaq (NASDAQ:QQQ) down a full 1%. The Dow (DIA +0.4%) remains higher, courtesy of a post-earnings 9% moonshot in Nike.
- Biotechs (IBB -5.7%) and Pharmaceuticals (XPH -5.9%) are hardest hit, continuing to feel the pressure from Hillary Clinton's assault on drug-pricing. Gilead (GILD -2.5%), Biogen (BIIB -3.5%), Celgene (CELG -5.4%), Amgen (AMGN -3.6%), Allergan (AGN -4%), Mylan (MYL -5.6%).
- ETFs: IBB, IYH, XLV, XBI, VHT, PJP, BBH, FBT, HQH, CURE, XPH, HQL, PBE, FXH, RXL, IHE, FHLC, SBIO, PPH, RYH, BBC, THQ, BBP, RXD, LABU, LABD, UBIO, ZBIO
Tue, Sep. 22, 2:07 AM
- Democratic presidential candidate Hillary Clinton is scheduled to outline a plan to rein in prescription drug costs in Iowa later today, after vowing on Twitter to go after "price-gouging" by drug companies.
- The tweet brought down the biotech sector yesterday, with the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) plunging 4.5%.
- Several details of the new plan have been provided by the Clinton campaign ahead of the speech: A $250 monthly cap on the amount chronic pain patients would have to pay for prescription medications, approving more generic/imported drugs, forcing pharmaceutical companies to reinvest their profits into R&D and ending their ability to write off consumer advertising as a business expense.
- ETFs: XBI, BIB, BBH, FBT, HQL, PBE, BIS, SBIO, BBC, BBP, UBIO, LABU, LABD, ZBIO
- Previously: Biotechs take it on the chin after Hillary tweet about plan to address drug price gouging; IBB down 5% (Sep. 21 2015)
Mon, Sep. 21, 12:56 PM
- The iShares Nasdaq Biotechnology Index Fund (IBB -5%) is down on increased volume, as well as many other ETFs and individual stocks, in apparent response by a tweet by presidential candidate Hillary Clinton stating that price gouging in the specialty drug market is outrageous. Tomorrow, she will "lay out a plan" to take it on.
- ETFs: IBB, XBI, BBH, FBT, HQL, PBE, SBIO, BBC, BBP, LABD, UBIO, LABU, ZBIO
Fri, Sep. 18, 1:36 PM
Tue, Jun. 23, 9:22 AM
- The ProShares UltraPro Nasdaq Biotechnology ETF (NASDAQ:UBIO) and the UltraPro Short Nasdaq Biotechnology ETF (NASDAQ:ZBIO) open for business on the Nasdaq today. They join other ProShares biotech ETFs, BIB and BIS.
- Last month, Direxion launched a triple-levered bullish biotech ETF, LABU.
- ETFs: IBB, XBI, BBH, FBT, HQL, PBE, SBIO, BBC, BBP, LABU, LABD
Fri, Jun. 19, 2:03 PM
Tue, May 5, 4:09 AM
- Global annual spending on cancer drugs in 2014 hit $100B (+10% Y/Y) for the first time, largely due to rising drug prices and increased incidence of cancer.
- "Earlier diagnosis, longer treatment duration and increased effectiveness of drug therapies are contributing to rising levels of spending on medicines for cancer," the IMS said in a report.
- The figures raise even more questions of affordability as the pharmaceuticals industry prepares to launch a fresh generation of treatments that promise to push costs even higher.
- ETFs: XBI, PJP, BBH, FBT, XPH, PBE, IHE, SBIO, PPH, BBC, BBP
- Related: U.S. drug spending rose 13% in 2014 (Apr. 14 2015)
- Related: Is hefty specialty drug spending the new normal? (Mar. 10 2015)
- Related: Global drug tab will breach trillion dollar mark this year (Nov. 20 2014)
Fri, Mar. 20, 2:18 PM
Dec. 30, 2014, 1:49 PM
- In keeping with the trend of biotech focused launches in the last quarter, the ALPS Medical Breakthroughs ETF (Pending:SBIO) will be the last launch of 2014.
- SBIO is designed to capture research and development opportunities in the biotechnology and pharmaceutical industries through small-cap and mid-cap biotechnology stocks listed in the U.S.
- Firms with with one or more drugs in Phase II or Phase III FDA clinical trials, with a market cap between $200 million and $5 billion, will be prime candidates for investment.
- Other domestic biotech ETFs: XBI, BBH, FBT, PBE, BBC, BBP
| Dec. 30, 2014, 1:49 PM | Comment!
Dec. 19, 2014, 1:55 PM
Dec. 17, 2014, 10:51 AM
- The BioShares Biotechnology Clinical Trials Fund (NASDAQ:BBC) will track an index of biotechnology companies with a principal focus on running human clinical trials, while the BioShares Biotechnology Products Fund (NASDAQ:BBP) will cover biotechnology companies with one or more drugs approved by the FDA and in commercial production.
- Both ETFs feature an equal weight index strategy, giving smaller firms a chance to make a meaningful impact on fund movements.
- “Our BioShares funds are designed with the current biotechnology market in mind and offer investors unique and diversified portfolios of entrepreneurial biotechnology stocks by applying our rules-based index methodology,” said LifeSci Index Partners co-founder, Paul Yook in a statement.
- Other biotech ETFs: XBI, BBH, FBT, PBE
Oct. 31, 2014, 12:47 PM
- The ARK Genomic Revolution Multi-Sector ETF (NYSEARCA:ARKG) is an actively managed fund that focuses on companies linked to the genomic industry across a number of sectors.
- The ARK Innovation ETF (NYSEARCA:ARKK) will cover all three investment themes ARK now offers ETF coverage of; industrials through the ARK Industrial Innovation ETF (NYSEARCA:ARKQ), technology through the ARK Web x.0 ETF (NYSEARCA:ARKW) and genomics with ARKG.
- "Our composite fund is a product of our approach to active management and can bring balance back to portfolios that have become increasingly benchmark-sensitive. Pulling across industries including life sciences, robotics, energy storage, social media, and cloud computing, ARKK will hold some of the most dynamic and innovative companies in the world," stated Cathie Wood, founder and CEO of ARK Investment Management, in a press release.
- Other broad technology ETFs: IPK, IXN
- Other biotech ETFs: XBI, BBH, FBT, PBE
Oct. 26, 2014, 9:44 AM
- Both groups experienced large corrections from February through April and have since corrected, but Biotech has massively outperformed the internet group over the last couple of months.
- Since 2013, Technology SPDR (NYSEARCA:XLK) +38.4%, iShares NASDAQ Biotechnology Index (NASDAQ:IBB) +109.3%.
- Source: Bespoke
- ETFs: XLK, XBI, VGT, BBH, SOXL, FBT, FDN, PBE, TECL, USD, SMH, IYZ, TDIV, IYW, ROM, VOX, SOXX, XSD, SOXS, PBS, TECS, FTEC, RYT, IGV, IGM, QTEC, FXL, PSI, PSCT, IGN, SSG, MTK, REW, PXQ, XTL, XSW, PSJ, PTF, FCOM, LTL, TLL
Jul. 8, 2014, 12:26 PM
- Leading this week's decline are a lot of the same names which led March's "momo" selloff, among them the biotechs (XBI -4.5%) and social media (SOCL -4.4%). Also familiar, small caps (IWM -1.5%) are off more than the other major indexes.
- Doing their jobs are the low volatility ETFs like SPLV (SPLV) and USMV (USMV -0.2%), as well as defensive sectors like the utilities (XLU +0.6%).
- Raymond James' typically bullish Jeffrey Saut is out with a note calling for the first decent pullback of the year - a 10-12% decline - to commence later this month or early August, and he suggests investors begin raising cash.
- Biotech ETFs: XBI, BBH, FBT, PBE
- Low-vol ETFs: SPLV, LGLV, CFA, CFO
- Utility ETFs: XLU, IDU, VPU, UPW, FUTY, RYU, FXU, PUI, SDP, PSCU
Jun. 9, 2014, 2:53 PM
- Those ETFs with more small- and mid-cap exposure like the SPDR S&P Biotech ETF (XBI +5.7%) and the PowerShares Dynamic Biotechnology & Genome Portfolio (PBE +7.4%) are partying. It also turns out the XBI and PBE are the two largest holders of Idenix stock.
- Biotech ETFs with a focus on large caps - the iShares Nasdaq Biotechnology ETF (IBB +0.5%) and the Market Vectors Biotech ETF (BBH +0.4%) - are having more subdued sessions.
- Previously: Merck buys Idenix
- The rally in small cap biotech fueling a positive session for small caps overall, with the Russell 2000's (IWM +0.7%) gain outpacing the flat action in the big-cap averages.
XBI vs. ETF Alternatives
The SPDR® S&P® Biotech ETF, before expenses, seeks to closely match the returns and characteristics of the S&P Biotechnology Select IndustryTM Index. Our approach is designed to provide portfolios with low portfolio turnover, accurate tracking, and lower costs.
See more details on sponsor's website
See more details on sponsor's website
Other News & PR